Spots Global Cancer Trial Database for Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Official Title: Phase 2 Open-Label Study of Volociximab (M200) in Patients With Metastatic Renal Cell Carcinoma
Study ID: NCT00100685
Interventions
Study Description
Brief Summary: This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) and is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 70400, Los Angeles, California, United States
Site Reference ID/Investigator# 70401, New York, New York, United States
Site Reference ID/Investigator# 70399, Cleveland, Ohio, United States
Contact Details
Name: Mihail Obrocea, MD
Affiliation: Abbott
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
